Amanda Fabra-García

Amanda Fabra-García

Auto-generated profile, based on publicly available information

Amanda Fabra-García

Department of Medical Microbiology, Radboud University Medical Center

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
WSWill J. R. Stone
Will J. R. Stone
JCJoseph J. Campo
Joseph J. Campo
AOAndré Lin Ouédraogo
André Lin Ouédraogo
LMLisette Meerstein-Kessel
Lisette Meerstein-Kessel
IMIsabelle Morlais
Isabelle Morlais
MJMatthijs M. Jore
Matthijs M. Jore
Infection withPlasmodiumcan elicit antibodies that inhibit parasite survival in the mosquito, when they are ingested in an infectious blood meal. Here, we determine the transmission-reducing activity (TRA) of naturally acquired antibodies from 648 malaria-exposed individuals using lab-based mosquito-feeding assays. Transmission inhibition is significantly associated with antibody responses to Pfs48/45, Pfs230, and to 43 novel gametocyte proteins assessed by protein microarray. In field-based mosquito-feeding assays the likelihood and rate of mosquito infection are significantly lower for individuals reactive to Pfs48/45, Pfs230 or to combinations of the novel TRA-associated proteins. We also show that naturally acquired purified antibodies against key transmission-blocking epitopes of Pfs48/45 and Pfs230 are mechanistically involved in TRA, whereas sera depleted of these antibodies retain high-level, complement-independent TRA. Our analysis demonstrates that host antibody responses to gametocyte proteins are associated with reduced malaria transmission efficiency from humans to mosquitoes.

20 May 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
MRMeta Roestenberg
Meta Roestenberg
JWJona Walk
Jona Walk
SBSaskia C. van der Boor
Saskia C. van der Boor
MLMarijke C. C. Langenberg
Marijke C. C. Langenberg
MHMarie-Astrid Hoogerwerf
Marie-Astrid Hoogerwerf
RSRobert W. Sauerwein
Robert W. Sauerwein
The genetically attenuated malaria vaccine PfSPZ-GA1 is safe, immunogenic, and has suboptimal protective efficacy in people.

1 June 2016 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
VSV. Sanchez-Merino
V. Sanchez-Merino
AFA. Fabra-Garcia
A. Fabra-Garcia
NGN. Gonzalez
N. Gonzalez
DNDavid Nicolás
David Nicolás
AMA. Merino-Mansilla
A. Merino-Mansilla
EYEloísa Yuste
Eloísa Yuste
A fraction of HIV-1 patients are able to generate broadly neutralizing antibodies (bNAbs) after 2 to 4 years of infection. In rare occasions such antibodies are observed close to the first year of HIV-1 infection but never within the first 6 months. In this study, we analyzed the neutralization breadth of sera from 157 antiretroviral-naive individuals who were infected for less than 1 year. A range of neutralizing activities was observed with a previously described panel of six recombinant viruses from five different subtypes (M. Medina-Ramirez et al., J Virol85:5804–5813, 2011,http://dx.doi.org/10.1128/JVI.02482-10). Some sera were broadly reactive, predominantly targeting envelope epitopes within the V2 glycan-dependent region. The neutralization breadth was positively associated with time postinfection (P= 0.0001), but contrary to what has been reported for chronic infections, no association with the viral load was observed. Notably, five individuals within the first 6 months of infection (two as early as 77 and 96 days postinfection) showed substantial cross-neutralization. This was confirmed with an extended panel of 20 Env pseudoviruses from four different subtypes (two in tier 3, 14 in tier 2, and four in tier 1). Sera from these individuals were capable of neutralizing viruses from four different subtypes with a geometric mean 50% infective dose (ID50) between 100 and 800. These results indicate that induction of cross-neutralizing responses, albeit rare, is achievable even within 6 months of HIV-1 infection. These observations encourage the search for immunogens able to elicit this kind of response in preventive HIV-1 vaccine approaches.IMPORTANCEThere are very few individuals able to mount broadly neutralizing activity (bNA) close to the first year postinfection. It is not known how early in the infection cross-neutralizing responses can be induced. In the present study, we show that bNAbs, despite being rare, can be induced much earlier than previously thought. The identification of HIV-1-infected patients with these activities within the first months of infection and characterization of these responses will help in defining new immunogen designs and neutralization targets for vaccine-mediated induction of bNAbs.

20 May 2020 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
IRIsaie J. Reuling
Isaie J. Reuling
AMAntónio Mendes
António Mendes
GJGerdie M. de Jong
Gerdie M. de Jong
AFAmanda Fabra-García
Amanda Fabra-García
HNHelena Nunes-Cabaço
Helena Nunes-Cabaço
Miguel PrudêncioMiguel Prudêncio
Miguel Prudêncio
Clinical evaluation of genetically modified rodent malaria parasites for whole-sporozoite immunization against P. falciparum in healthy volunteers.

11 January 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
SSSusheel Kumar Singh
Susheel Kumar Singh
JPJordan Plieskatt
Jordan Plieskatt
BCBishwanath K. Chourasia
Bishwanath K. Chourasia
AFAmanda Fabra-García
Amanda Fabra-García
AGAsier Garcia-Senosiain
Asier Garcia-Senosiain
MTMichael Theisen
Michael Theisen
The cysteine-rich Pfs48/45 protein, a Plasmodium falciparum sexual stage surface protein, has been advancing as a candidate antigen for a transmission-blocking vaccine (TBV) for malaria. However, Pfs48/45 contains multiple disulfide bonds, that are critical for proper folding and induction of transmission-blocking (TB) antibodies. We have previously shown that R0.6C, a fusion of the 6C domain of Pfs48/45 and a fragment of PfGLURP (R0), expressed in Lactococcus lactis, was properly folded and induced transmission-blocking antibodies. Here we describe the process development and technology transfer of a scalable and reproducible process suitable for R0.6C manufacturing under current Good Manufacturing Practices (cGMP). This process resulted in a final purified yield of 25 mg/L, sufficient for clinical evaluation. A panel of analytical assays for release and stability assessment of R0.6C were developed including HPLC, SDS-PAGE, and immunoblotting with the conformation-dependent TB mAb45.1. Intact mass analysis of R0.6C confirmed the identity of the product including the three disulfide bonds and the absence of post-translational modifications. Multi-Angle Light Scattering (MALS) coupled to size exclusion chromatography (SEC-MALS), further confirmed that R0.6C was monomeric (~70 kDa) in solution. Lastly, preclinical studies demonstrated that the R0.6C Drug Product (adsorbed to Alhydrogel®) elicited functional antibodies in small rodents and that adding Matrix-M™ adjuvant further increased the functional response. Here, building upon our past work, we filled the gap between laboratory and manufacturing to ready R0.6C for production under cGMP and eventual clinical evaluation as a malaria TB vaccine.

19 December 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CBCarolina Beltran-Pavez
Carolina Beltran-Pavez
CFCarolina B Ferreira
Carolina B Ferreira
AMAlberto Merino-Mansilla
Alberto Merino-Mansilla
AFAmanda Fabra-Garcia
Amanda Fabra-Garcia
MCMaria Casadellà
Maria Casadellà
VSVictor Sanchez-Merino
Victor Sanchez-Merino
Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody (bNAb) responses, but their induction in vivo by vaccination remains challenging. Considering that the ability of an epitope to elicit effective humoral immunity depends on its exposure on the virion, we have used a reverse genetics approach to select variants from an HIV-1 AC10_29 randomly mutated envelope library that showed increased affinity for a selected bNAb (4E10 bNAb targeting the HIV-1 MPER region). Isolated envelope sequences were analyzed by deep-sequencing showing a small number of dominant changes, including the loss of four potential N-linked glycosylation sites and disruption of the V1/V2 loop. Accordingly, the dominant variant (LR1-C1), showed not only increased affinity for MPER bNAbs 4E10 and 2F5, but also higher affinity for an additional antibody targeting the V3 loop (447-52D) that could be a consequence of an open conformation tier 1-like Env. Furthermore, the amino acids specific for the selected variant are associated with an increased sensitivity for 4E10 and 2F5 antibodies. In vivo studies showed that sera from mice immunized with LR1-C1 viruses possessed an improved neutralizing activity compared to the wild-type AC10_29 env. While Virus Like Particles (VLPs) carrying this envelope were unable to induce detectable neutralizing activity in immunized rabbits, one animal showed antibody response to the 4E10-proximal region. Our data establish a novel approach that has the potential to yield HIV envelope immunogen sequences that direct antibody responses to specific envelope regions.